Bone marrow is not fractionated. Results are reported with the exact percentage of donor engraftment. “Sensitivity: ±5%” indicates the minimum amount of control DNA marker detectable for this specimen. If more than one of the ten STR markers is informative, the average of all informative markers will be the final engraftment result.

Allogeneic hematopoietic cell transplant (HCT) is a therapeutic option available for treatment of numerous malignancies and inherited genetic disorders. Monitoring engraftment following allogeneic HCT is necessary for early documentation of engraftment, detection and timely treatment of graft rejection or early relapse. The presence of lympho-hematopoietic cells of donor origin after allogeneic HCT is referred to as “chimerism”. The kinetics of engraftment in different cell populations has been found to be different among T cells, Natural Killer (NK) cells, granulocytes and monocytes. Generally donor T cell chimerism has been found to lag behind donor myeloid chimerism. Early patterns of T and NK cell chimerism have predicted patients at increased risk of graft rejection and graft versus host disease. Hence lineage-specific chimerism (i.e. monitoring of engraftment is specific subset) may provide valuable clinical information in identifying patients at high risk for adverse clinical events.